Logo image of RLYB

RALLYBIO CORP (RLYB) Stock Fundamental Analysis

NASDAQ:RLYB - Nasdaq - US75120L1008 - Common Stock - Currency: USD

0.2651  +0.02 (+6.04%)

Fundamental Rating

3

Taking everything into account, RLYB scores 3 out of 10 in our fundamental rating. RLYB was compared to 568 industry peers in the Biotechnology industry. RLYB has a great financial health rating, but its profitability evaluates not so good. RLYB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

RLYB had negative earnings in the past year.
RLYB had a negative operating cash flow in the past year.
In the past 5 years RLYB always reported negative net income.
RLYB had a negative operating cash flow in each of the past 5 years.
RLYB Yearly Net Income VS EBIT VS OCF VS FCFRLYB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -84.83%, RLYB is not doing good in the industry: 71.30% of the companies in the same industry are doing better.
RLYB has a Return On Equity (-93.71%) which is in line with its industry peers.
Industry RankSector Rank
ROA -84.83%
ROE -93.71%
ROIC N/A
ROA(3y)-62.09%
ROA(5y)-46.14%
ROE(3y)-67.77%
ROE(5y)-49.9%
ROIC(3y)N/A
ROIC(5y)N/A
RLYB Yearly ROA, ROE, ROICRLYB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

RLYB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLYB Yearly Profit, Operating, Gross MarginsRLYB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

RLYB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RLYB has more shares outstanding
RLYB has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RLYB Yearly Shares OutstandingRLYB Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RLYB Yearly Total Debt VS Total AssetsRLYB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RLYB has an Altman-Z score of -6.89. This is a bad value and indicates that RLYB is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.89, RLYB is doing worse than 66.02% of the companies in the same industry.
There is no outstanding debt for RLYB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.89
ROIC/WACCN/A
WACC10.2%
RLYB Yearly LT Debt VS Equity VS FCFRLYB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

RLYB has a Current Ratio of 10.87. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RLYB (10.87) is better than 82.39% of its industry peers.
RLYB has a Quick Ratio of 10.87. This indicates that RLYB is financially healthy and has no problem in meeting its short term obligations.
RLYB has a better Quick ratio (10.87) than 82.57% of its industry peers.
Industry RankSector Rank
Current Ratio 10.87
Quick Ratio 10.87
RLYB Yearly Current Assets VS Current LiabilitesRLYB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

RLYB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.63%, which is quite impressive.
EPS 1Y (TTM)26.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

RLYB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.36% yearly.
RLYB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 256.09% yearly.
EPS Next Y26.9%
EPS Next 2Y11.53%
EPS Next 3Y9.06%
EPS Next 5Y2.36%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y256.09%

3.3 Evolution

RLYB Yearly Revenue VS EstimatesRLYB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2028 2029 2030 2031 500M 1B 1.5B
RLYB Yearly EPS VS EstimatesRLYB Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RLYB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RLYB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLYB Price Earnings VS Forward Price EarningsRLYB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLYB Per share dataRLYB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.53%
EPS Next 3Y9.06%

More info and screens

0

5. Dividend

5.1 Amount

RLYB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RALLYBIO CORP

NASDAQ:RLYB (4/21/2025, 8:00:01 PM)

0.2651

+0.02 (+6.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-13 2025-03-13/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners69.98%
Inst Owner Change1.86%
Ins Owners2.32%
Ins Owner Change0%
Market Cap11.03M
Analysts81.82
Price Target8.41 (3072.39%)
Short Float %0.92%
Short Ratio5.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.1%
Min EPS beat(2)14.53%
Max EPS beat(2)27.67%
EPS beat(4)4
Avg EPS beat(4)12%
Min EPS beat(4)2.79%
Max EPS beat(4)27.67%
EPS beat(8)7
Avg EPS beat(8)8.88%
EPS beat(12)9
Avg EPS beat(12)7.42%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-0.8%
EPS NQ rev (3m)0.91%
EPS NY rev (1m)26.78%
EPS NY rev (3m)26.78%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.34
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.18
EV/EBITDA N/A
EPS(TTM)-1.35
EYN/A
EPS(NY)-0.99
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0.02
BVpS1.48
TBVpS1.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.83%
ROE -93.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.09%
ROA(5y)-46.14%
ROE(3y)-67.77%
ROE(5y)-49.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.87
Quick Ratio 10.87
Altman-Z -6.89
F-Score4
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)12.47%
Cap/Depr(5y)114.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y26.9%
EPS Next 2Y11.53%
EPS Next 3Y9.06%
EPS Next 5Y2.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y256.09%
EBIT growth 1Y23.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-7.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.22%
OCF growth 3YN/A
OCF growth 5YN/A